Clinical study on gimeracil and oteracil porassium capsules and capecitabine respectively combined with do-cetaxel in the treatment of metastatic breast cancer
10.3760/cma.j.issn.1008-6706.2014.15.019
- VernacularTitle:替吉奥与卡培他滨分别联合多西他赛治疗转移性乳腺癌的临床研究
- Author:
Junling ZHANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Neoplasm metastasis;
Gimeracil and oteracil porassium;
Capecitabine;
Do-cetaxel
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;(15):2280-2282
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the effect of gimeracil and oteracil porassium capsules ( S-1 ) combined with docetaxel and capecitabine combined with docetaxel in the treatment of metastatic breast cancer .Methods Ac-cording to the digital table ,88 patients with metastatic breast cancer were randomly divided into the observation group and control group ,44 cases in each group .The observation group received S-1 combined with docetaxel treatment ,the control group received capecitabine combined with docetaxel treatment .The total effective rate ,progression free surviv-al,quality of life and the incidence of adverse reactions were compared between the two groups .Results The total effective rate of the observation group was 75.00%,which was significantly higher than 38.64%of the control group (χ2 =2.199,P<0.05).The progression free survival time in the observation group was (10.53 ±3.21) months, which was significantly longer than (5.72 ±2.10)months in the control group(t=0.667,P<0.05).After 3 months of follow-up,the body,social support,psychological,spiritual and other 4 factor scores of patients in the observation group were better than those in the control group (t=2.885,2.326,3.379,5.503,all P<0.05),the quality of life greatly improved .Conclusion The clinical efficacy of S-1 combined with docetaxel in the treatment of metastatic breast cancer is exact ,adverse reactions can be tolerated ,it can be used as a new clinical scheme of chemotherapy for metastatic breast cancer .
